MCK

McKesson Corporation (MCK) - Q2 2026 Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025 (Fiscal Q2 2026). McKesson Corporation is a diversified healthcare services leader. Commencing in this quarter, the Company implemented a new segment reporting structure consisting of four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. Norwegian operations are now classified as "Other" and held for sale.

Key Financial Metrics

Note: Gross profit margin for the three months ended Sept 30, 2025 was 3.43%.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 10% in Q2 and 16% YTD compared to the prior year, driven by market growth in North American Pharmaceutical (higher volumes from retail national accounts) and significant growth in Oncology & Multispecialty (specialty pharmaceutical sales and provider additions).
• Profitability Surge: Net income attributable to McKesson increased 361% in Q2 and 64% YTD. This was significantly aided by a lower effective tax rate (16.6% in Q2 vs. 46.3% prior year) due to a discrete tax benefit of $119 million from the release of a foreign valuation allowance.
• Expense Reduction: Total operating expenses decreased 20% in Q2 and 9% YTD. This reduction is largely due to the absence of a $643 million remeasurement charge related to the Canadian retail disposal group recorded in the prior year.
• Restructuring: Restructuring charges were $63 million in Q2 2026 compared to $171 million in Q2 2025, reflecting the winding down of prior initiatives and the start of new technology modernization efforts.

Guidance, Outlook, and Risks

• Acquisitions: The Company completed two major acquisitions in the Oncology & Multispecialty segment: PRISM Vision ($871 million) and Core Ventures ($2.5 billion). These were funded by cash on hand and a $2.0 billion public debt offering in May 2025.
• Divestitures: The Company entered an agreement to sell its Norwegian retail and distribution businesses (classified as held for sale). Additionally, the Company announced an intention to separate the Medical-Surgical Solutions segment into an independent company.
• Capital Allocation: The Board raised the quarterly dividend to $0.82 per share. The Company returned $1.6 billion to shareholders YTD via $1.4 billion in share repurchases and $179 million in dividends. Approximately $6.1 billion remains authorized for share repurchases.
• Litigation Risks: Significant contingent liabilities remain related to opioid litigation. Total estimated litigation liabilities were $5.72 billion as of September 30, 2025. The Company is vigorously defending against non-settled claims, including those in Baltimore and Philadelphia.
• Restructuring Outlook: The Company anticipates total charges of $650 million to $700 million for enterprise-wide technology modernization initiatives, expected to be substantially complete by fiscal 2028.

Investor Verification Checklist

• Acquisition Integration: Verify the financial contribution and integration progress of the Core Ventures and PRISM Vision acquisitions in the Oncology & Multispecialty segment.
• Opioid Litigation Exposure: Monitor developments in non-settled opioid cases (e.g., Baltimore, Philadelphia) and the adequacy of the $5.72 billion litigation reserve.
• Medical-Surgical Spin-off: Track the timeline and regulatory approvals for the planned separation of the Medical-Surgical Solutions segment.
• Working Capital Trends: Review the impact of the Rite Aid bankruptcy provision ($189 million bad debt charge YTD) on future receivables and cash flow.
• Debt Covenants: Confirm continued compliance with debt covenants, specifically the Total Debt to Consolidated EBITDA ratio, given the increased debt load from recent acquisitions.